Search Result

Results for "

GSK-3β inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GSK-3 (143) AAK1 (1) Akt (9) AMPK (2) Amyloid-β (10) Antibiotic (8) Apoptosis (20) Aurora Kinase (7) Autophagy (14) Bacterial (7) Bcl-2 Family (1) Beta-secretase (1) Biochemical Assay Reagents (1) c-Met/HGFR (2) c-Myc (1) Cadherin (1) CaMK (1) Casein Kinase (1) Caspase (3) CDK (28) CDKL (1) CFTR (1) Cholinesterase (ChE) (7) CXCR (1) Cytochrome P450 (1) Dopamine Receptor (1) DYRK (6) ERK (5) HDAC (3) Heme Oxygenase (HO) (1) HIV (1) HSP (2) HSV (2) IAP (1) IKK (2) Influenza Virus (1) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (3) JAK (4) JNK (12) Keap1-Nrf2 (1) Lipoxygenase (1) LRRK2 (1) MAP3K (1) MEK (2) Microtubule/Tubulin (1) Mitophagy (4) MMP (1) Monoamine Oxidase (1) NF-κB (11) NO Synthase (3) Organoid (4) p38 MAPK (9) Parasite (2) PARP (1) PDK-1 (1) PERK (1) Phosphatase (1) PI3K (5) Pim (2) PKA (4) PKC (8) PPAR (2) Prostaglandin Receptor (1) PROTACs (2) Proton Pump (2) RANKL/RANK (1) Reactive Oxygen Species (ROS) (5) Reference Standards (9) ROS Kinase (1) SGK (1) Src (1) Syk (1) Tau Protein (8) TGF-β Receptor (1) Tyrosinase (1) VD/VDR (2) VEGFR (2) Wnt (11) β-catenin (9)
By Research Areas:	Cancer (97) Cardiovascular Disease (10) Endocrinology (1) Infection (17) Inflammation/Immunology (36) Metabolic Disease (34) Neurological Disease (85)

By Targets:

GSK-3 (143)

AAK1 (1)

Akt (9)

AMPK (2)

Amyloid-β (10)

Antibiotic (8)

Apoptosis (20)

Aurora Kinase (7)

Autophagy (14)

Bacterial (7)

Bcl-2 Family (1)

Beta-secretase (1)

Biochemical Assay Reagents (1)

c-Met/HGFR (2)

c-Myc (1)

Cadherin (1)

CaMK (1)

Casein Kinase (1)

Caspase (3)

CDK (28)

CDKL (1)

CFTR (1)

Cholinesterase (ChE) (7)

CXCR (1)

Cytochrome P450 (1)

Dopamine Receptor (1)

DYRK (6)

ERK (5)

HDAC (3)

Heme Oxygenase (HO) (1)

HIV (1)

HSP (2)

HSV (2)

IAP (1)

IKK (2)

Influenza Virus (1)

Integrin (1)

Interleukin Related (1)

Isotope-Labeled Compounds (3)

JAK (4)

JNK (12)

Keap1-Nrf2 (1)

Lipoxygenase (1)

LRRK2 (1)

MAP3K (1)

MEK (2)

Microtubule/Tubulin (1)

Mitophagy (4)

MMP (1)

Monoamine Oxidase (1)

NF-κB (11)

NO Synthase (3)

Organoid (4)

p38 MAPK (9)

Parasite (2)

PARP (1)

PDK-1 (1)

PERK (1)

Phosphatase (1)

PI3K (5)

Pim (2)

PKA (4)

PKC (8)

PPAR (2)

Prostaglandin Receptor (1)

PROTACs (2)

Proton Pump (2)

RANKL/RANK (1)

Reactive Oxygen Species (ROS) (5)

Reference Standards (9)

ROS Kinase (1)

SGK (1)

Src (1)

Syk (1)

Tau Protein (8)

TGF-β Receptor (1)

Tyrosinase (1)

VD/VDR (2)

VEGFR (2)

Wnt (11)

β-catenin (9)

By Research Areas:

Cancer (97)

Cardiovascular Disease (10)

Endocrinology (1)

Infection (17)

Inflammation/Immunology (36)

Metabolic Disease (34)

Neurological Disease (85)

181

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: GSK-3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-164907

GSK-3β inhibitor 22	GSK-3	Neurological Disease
GSK-3β inhibitor 22 (compound 20o) is a *GSK-3β* inhibitor with an IC₅₀ of 3.1 nM. GSK-3β inhibitor 22 has the potential of the study of Alzheimer's disease .

HY-148133

GSK-3β inhibitor 12	GSK-3	Neurological Disease
GSK-3β inhibitor 12 (compound 15) is an inhibitor of *GSK-3β. GSK-3β* inhibitor 12 inhibits 49.11% and 37.11% activity of 25 μM and 50 μM GSK-3β, respectively. GSK-3β inhibitor 12 can be used for the research of neurodegenerative diseases .

HY-130795

GSK-3β inhibitor 2 1 Publications Verification	GSK-3	Neurological Disease
GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active *GSK-3β* inhibitor with an IC₅₀ of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease .

HY-147134

GSK-3β inhibitor 10	GSK-3	Neurological Disease
GSK-3β inhibitor 10 (compound 14a) is a highly potent *GSK-3β* inhibitor with an IC₅₀ value of 80.5 nM. GSK-3β inhibitor 10 can be used for researching Alzheimer’s disease .

HY-149542

GSK-3β inhibitor 15	Tau Protein Apoptosis GSK-3	Neurological Disease
GSK-3β inhibitor 15 (Compound 54) is a *GSK-3β* inhibitor (IC₅₀: 3.4 nM). GSK-3β inhibitor 15 inhibits Aβ_1-42-induced GSK-3β and tau protein phosphorylation. GSK-3β inhibitor 15 inhibits LPS-induced iNOS expression. GSK-3β inhibitor 15 has neuroprotective effects on Aβ_1-42-induced neurotoxicity. GSK-3β inhibitor 15 can be used for research of Alzheimer’s disease (AD) .

HY-168857

GSK-3β inhibitor 24	GSK-3 Tau Protein β-catenin	Neurological Disease
GSK-3β inhibitor 24 (Compound 41) is a potent *GSK-3β* inhibitor with an IC₅₀ of 0.22 nM. GSK-3β inhibitor 24 increases GSK-3β phosphorylation at Ser9 site dose-dependently. GSK-3β inhibitor 24 inhibits the hyperphosphorylation of tau protein by decreasing the p-tau-Ser396 abundance. GSK-3β inhibitor 24 up-regulates β-catenin and neurogenesis-related markers (GAP43 and MAP-2). GSK-3β inhibitor 24 demonstrates remarkable anti-Alzheimer's disease (AD) effects .

HY-169024

GSK-3β inhibitor 19	GSK-3	Neurological Disease Inflammation/Immunology
GSK-3β inhibitor 19 (compound 36) is a *GSK-3β* inhibitor, with IC₅₀ of 70 nM. GSK-3β inhibitor 19 can be used in anti-inflammatory and Alzheimer's disease related research .

HY-143261

GSK-3β inhibitor 7	GSK-3	Metabolic Disease Inflammation/Immunology Cancer
GSK-3β inhibitor 7 is a *GSK-3β* inhibitor with an IC₅₀ value of 5.25 μM. GSK-3β inhibitor 7 is inserted into the ATP-binding binding pocket of GSK-3β and forms hydrogen-bond. GSK-3β inhibitor 7 shows high hepatocyte glucose uptake (83.5%), and can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder .

HY-169602

GSK-3β inhibitor 26	GSK-3	Neurological Disease Inflammation/Immunology Cancer
GSK-3β inhibitor 26 (Compound D14) is a *GSK-3β* inhibitor with an IC₅₀ of 18.23 μM. GSK-3β inhibitor 26 can be used in the research of cancer, inflammation and neurodegenerative diseases .

HY-143260

GSK-3β inhibitor 6	GSK-3	Metabolic Disease Inflammation/Immunology Cancer
GSK-3β inhibitor 6 is a potent *GSK-3β* inhibitor with an IC₅₀ value of 24.4 μM. GSK-3β inhibitor 6 shows high hepatocyte glucose uptake (38%). GSK-3β inhibitor 6 can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder .

HY-174272

GSK-3β inhibitor 27	GSK-3 Amyloid-β	Neurological Disease
GSK-3β inhibitor 27 (Compound 1c) is a reversible and competitive *GSK-3β* inhibitor with an IC₅₀ value of 2.2 μM. GSK-3β inhibitor 27 inhibits tau hyperphosphorylation, reduces Aβ protein aggregation and possesses metal chelation and neuroprotective potential. GSK-3β inhibitor 27 is promising for research of neurodegenerative diseases (such as Alzheimer’s disease) .

HY-126144

GSK-3β inhibitor 1 3 Publications Verification	GSK-3	Metabolic Disease Cancer
GSK-3β inhibitor 1 (compound 3a) inhibits *GSK-3β* with an IC₅₀ of 4.19 nM. GSK-3β inhibitor 1 demonstrates high antidiabetic efficacy in obese Streptozotocin (HY-13753)-treated rats .

HY-162638

GSK-3β inhibitor 18	GSK-3	Neurological Disease
GSK-3β inhibitor 18 (compound 2) is a potent inhibitor of *GSK-3β, with the IC₅₀* of 0.0021 μM .

HY-120902

GSK-3β inhibitor 8	Wnt GSK-3	Inflammation/Immunology
GSK-3β inhibitor 8, a thiophenacil derivative, is an effective and selective inhibitor of *GSK-3β* (IC₅₀=64 nM). GSK-3β inhibitor 8 negatively regulated Wnt signaling pathway and stimulated β cell proliferation .

HY-162913

GSK-3β inhibitor 20	GSK-3	Neurological Disease
GSK-3β inhibitor 20 (compound 3A) is an potent inhibitor of GSK-3β with an IC₅₀ value of 74.4 nM .

HY-148132

GSK-3β inhibitor 11	GSK-3	Neurological Disease
GSK-3β inhibitor 11 (compound 21) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC₅₀=10.02 μM). GSK-3β inhibitor 11 can be used in neurodegenerative disease research .

HY-141480

GSK-3β inhibitor 3 1 Publications Verification	GSK-3 Apoptosis	Cancer
GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC₅₀ of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia .

HY-153760

GSK-3β inhibitor 14	GSK-3	Neurological Disease Metabolic Disease
GSK-3β inhibitor 14 (Compound 6i), benzothiazepinone derivative, is a weak *GSK-3β* inhibitor (IC₅₀ >100 μM) .

HY-168079

GSK-3β inhibitor 21	GSK-3 Tau Protein	Neurological Disease Inflammation/Immunology
GSK-3β inhibitor 21 (compound 44) is an ATP-competitive *GSK-3β* inhibitor (IC₅₀=6.06 μM) with anti-amyloid aggregation and tau phosphorylation inhibitory activities. GSK-3β inhibitor 21 can be used in the study of Alzheimer's disease .

HY-161458

GSK-3β inhibitor 16	GSK-3 Tau Protein	Neurological Disease
GSK-3β inhibitor 16 (compound 7c) is a *GSK-3β* inhibitor with the IC₅₀ of 4.68 nM. GSK-3β inhibitor 16 decreases Tau hyperphosphorylated aggregate and alleviates cognitive impairments in the Scopolamin (HY-N0296)-induced model in mice .

HY-163748

GSK-3β inhibitor 17	GSK-3	Inflammation/Immunology
GSK-3β inhibitor 17 (compound 5 n) is a potent *GSK-3β* inhibitor. GSK-3β inhibitor 17 decreases cisplatin (HY-17394) induced p-p65, KIM-1 protein and mRNA expression. GSK-3β inhibitor 17 decreases cisplatin induced TNF-α, IL-1β, IL-6 and MCP-1 mRNA expression. GSK-3β inhibitor 17 shows anti-inflammation effect and has the potential for the research of acute kidney injury .

HY-149054

GSK-3β inhibitor 13	GSK-3 Tau Protein AAK1 Pim PKC	Neurological Disease
GSK-3β inhibitor 13 (compound 47) is an orally active and potent *GSK-3β* inhibitor with blood-brain permeability. GSK-3β inhibitor 13 inhibits *GSK-3β* and GSK-3α with IC₅₀s of 0.73 nM and 0.35 nM, respectively. GSK-3β inhibitor 13 significantly decreases the phosphorylation of tau (IC₅₀=58 nM), which leads the formation of the neurofibrillary tangles associated with Alzheimer's disease .

HY-170491

GSK-3β inhibitor 23	GSK-3	Infection Neurological Disease
GSK-3β inhibitor 23 (Compound 11726169) is the inhibitor for glycogen synthase kinase-3, that inhibits *GSK-3β* and GSK-3α with IC₅₀ of 12.1 nM and 18.8 nM. GSK-3β inhibitor 23 exhibits antiviral activity against HIV 1. GSK-3β inhibitor 23 exhibits good metabolic stablility in mouse/human liver microsomes and plasma, but poor Caco-2 permeability (which predicts low oral bioavailability) .

HY-169606

GSK-3β inhibitor 25	GSK-3	Neurological Disease Metabolic Disease
GSK-3β inhibitor 25 (Compound 6h) exhibits a weak inhibitory activity against *GSK-3β* wih an IC₅₀>100 μM .

HY-14679

GSK3β inhibitor II	GSK-3	Neurological Disease
GSK3β inhibitor II is an inhibitor of *GSK3β. GSK3β* inhibitor II can be used for research of Alzheimer’s disease (AD) .

HY-11012

TDZD-8 10+ Cited Publications GSK-3β inhibitor I; NP 01139	GSK-3	Cancer
TDZD-8 is an inhibitor of *GSK-3β, with an IC₅₀* of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC₅₀s of >100 μM.

HY-10512

AR-A014418 15+ Cited Publications AR 0133418; GSK 3β inhibitor VIII; AR 014418	GSK-3	Metabolic Disease Cancer
AR-A014418 is a potent, selective and ATP-competitive *GSK3β* inhibitor (IC₅₀=104 nM; K_i=38 nM) .

HY-10512R

AR-A014418 (Standard) AR 0133418 (Standard); GSK 3β inhibitor VIII (Standard); AR 014418 (Standard)	Reference Standards GSK-3	Metabolic Disease Cancer
AR-A014418 (Standard) is the analytical standard of AR-A014418. This product is intended for research and analytical applications. AR-A014418 is a potent, selective and ATP-competitive GSK3β inhibitor (IC50=104 nM; Ki=38 nM) .

HY-10512S

AR-A014418-d3 AR 0133418-d₃; GSK 3β inhibitor VIII-d₃; AR 014418-d₃	Isotope-Labeled Compounds GSK-3	Metabolic Disease Cancer
AR-A014418-d₃ is the deuterium labeled AR-A014418. AR-A014418 is a potent, selective, and ATP-competitive GSK3β inhibitor (IC₅₀=104 nM; K_i=38 nM) .

HY-P1173

L803-mts Myristoylated L 803; GSK-3β inhibitor XIII	GSK-3 Amyloid-β	Neurological Disease
L803-mts (Myristoylated L 803) is a selective and substrate-competitive GSK-3 peptide inhibitor (IC₅₀: 40 μM). L803-mts also reduces Aβ deposits and ameliorates cognitive deficits in 5XFAD mice. L803-mts shows antidepressive effect in the forced swimming test .

HY-126144A

*(E/Z)-GSK-3β* inhibitor 1**	GSK-3	Metabolic Disease
(E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC₅₀ of 4.9 nM .

HY-117194

18BIOder	HIV GSK-3	Infection
18BIOder is a neuroprotective *GSK-3β inhibitor, highly selectively inhibiting* HIV-1 .

HY-136679

TD114-2	GSK-3	Neurological Disease Metabolic Disease
TD114-2 (cmpound 29) is a potent and highly selective inhibitor of glycogen synthase kinase-3β (GSK-3β) (IC₅₀=48 nM). TD114-2 is associated with the hydrogen bond formation of arginine 141 (ARG141) specific to *GSK-3β, an amino acid that is often a negatively charged residue in other kinases, which determines the high selectivity of GSK-3β. TD114-2 can be used in the study of diabetes, neurodegenerative diseases and other diseases associated with GSK-3β* .

HY-10096

TCS2002	GSK-3	Neurological Disease
TCS2002 (Compound 9b) is a highly selective, orally bioavailable and potent *GSK-3β* inhibitor with the IC₅₀ of 35 nM. TCS2002 shows good pharmacokinetic profiles including favorable BBB penetration. TCS2002 can be used for the research of Alzheimer’s disease .

HY-149845

PROTAC GSK-3β Degrader-1	GSK-3 PROTACs	Neurological Disease
PROTAC GSK-3β Degrader-1 (compound 1) is a degrader targets *GSK-3β* degradation with an IC₅₀ value of 833 nM. PROTAC GSK-3β Degrader-1 contains SB-216763 (a GSK-3β inhibitor), a PEG linker and a CRBN (E3 ligase liand). PROTAC GSK-3β Degrader-1 reduces the neurotoxicity induced by Aβ_25-35 peptide and CuSO₄. PROTAC GSK-3β Degrader-1 can be used to research in Alzheimer's disease .

HY-P10605

GSK3β-peptide	Akt GSK-3	Cancer
GSK3β-peptide is a substrate mimetic peptide of glycogen synthase kinase 3-β (GSK3-β) that can bind to the active site of *GSK3-β* and mimic the behavior of a real substrate. GSK3β-peptide can be used to develop substrate mimetic inhibitors of Akt as potential anticancer drugs .

HY-154852

GSK-3 inhibitor 4	GSK-3 CDK	Neurological Disease
GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of GSK-3, CDK2, and CDK5, with IC₅₀ values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies .

HY-14872

Tideglusib 5+ Cited Publications NP031112	GSK-3	Neurological Disease
Tideglusib (NP031112) is an irreversible GSK-3 inhibitor with IC₅₀s of 5 nM and 60 nM for GSK-3β ^WT (1 h preincubation) and GSK-3β ^C199A (1 h preincubation), respectively.

HY-172171

GSK3β-IN-2	GSK-3 β-catenin Wnt	Neurological Disease
GSK3β-IN-2 (Compound S01) is the inhibitor for *GSK3β* with an IC₅₀ of 0.35 nM. GSK3β-IN-2 activates Wnt/β-catenin signaling pathway, promotes neurogenesis and neurite growth. GSK3β-IN-2 inhibits Aβ-induced tau hyperphosphorylation at Ser396, reduces the formation of neurofibrillary tangles. GSK3β-IN-2 ameliorates Alzheimer's Disease in zebrafish model .

HY-W098905

GSK3β-IN-3	GSK-3 Cytochrome P450 Amyloid-β Tau Protein	Neurological Disease
GSK3β-IN-3 is an ATP-competitive *GSK-3β* inhibitor (IC₅₀ = 0.90 μM) . GSK3β-IN-3 can reduce the phosphorylation level of tau protein in the BR5706 strain and reduce the deposition of Aβ aggregates in the CL2006 strain, and can be used to research Alzheimer's disease (AD) .

HY-10590

TWS119 25+ Cited Publications	Wnt GSK-3 Autophagy	Neurological Disease Cancer
TWS119 is an inhibitor of *GSK-3β, with an IC₅₀* of 30 nM, and activates the wnt/β-catenin pathway.

HY-12292

IM-12 5+ Cited Publications	Wnt GSK-3	Cancer
IM-12 is an inhibitor of *GSK-3β, with an IC₅₀* of 53 nM, and also enhances Wnt signalling.

HY-169632

GSK3β-IN-1	GSK-3	Neurological Disease
GSK3β-IN-1 (compound 1) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC₅₀=65 nM), which can be used in the study of Alzheimer's disease .

HY-151260

AChE/BACE1/GSK3β-IN-1	Beta-secretase Cholinesterase (ChE) GSK-3	Neurological Disease
AChE/BACE1/GSK3β-IN-1 is an orally active triple inhibitor of *AChE/BACE1/GSK3β. AChE/BACE1/GSK3β-IN-1 has effective inhibitory activity against AChE, BACE1 and GSK3β* with IC₅₀ values of 1.0 μM, 20 μM and 15 μM, respectively. AChE/BACE1/GSK3β-IN-1 has good blood-brain barrier penetrability, suitable bioavailability. AChE/BACE1/GSK3β-IN-1 can be used for the research of Alzheimer's disease (AD) .

HY-110074

TWS119 TFA	Others Wnt	Others
TWS119 TFA is a specific inhibitor of *GSK-3β, with an IC₅₀* of 30 nM, and activates the wnt/β-catenin pathway.

HY-144826

ZDWX-25	GSK-3	Neurological Disease
ZDWX-25 is a highly potent *GSK-3β* and DYRK1A dual inhibitor with an IC₅₀ value of 71 nM for GSK-3β. ZDWX-25 possesses significant cytotoxic activities against SH-SY5Y and HL-7702 cells. ZDWX-25 can be used for researching alzheimer's disease .

HY-144290

ARN25068	GSK-3 DYRK	Neurological Disease
ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation .

HY-173494

GSK-3β/CK-1δ-IN-1	GSK-3 Casein Kinase	Cancer
GSK-3β/CK-1δ-IN-1 (8d) is a dual and blood-brain barrier penetrated *GSK-3β* / CK-1δ inhibitor, with IC₅₀ values of 0.77 μM for GSK-3β and 0.57 μM for CK-1δ, respectively. GSK-3β/CK-1δ-IN-1 (8d) can be used in the research for neuroblastoma .

HY-133102

Dihydronarwedine Lycoraminone	GSK-3	Neurological Disease
Dihydronarwedine (Lycoraminone) is the alkaloid. Dihydronarwedine inhibits 39% activity of glycogen synthase kinase-3β (GSK-3β) at a concentration of 10 μM .

HY-107530

3F8	GSK-3	Cardiovascular Disease Metabolic Disease Cancer
3F8 is a potent and selective *GSK-3β* inhibitor that could be useful as new reagent and potential therapeutic candidate for GSK3 related diseases .

Cat. No.	Product Name	Target	Research Area

HY-P1173

L803-mts Myristoylated L 803; GSK-3β inhibitor XIII	GSK-3 Amyloid-β	Neurological Disease
L803-mts (Myristoylated L 803) is a selective and substrate-competitive GSK-3 peptide inhibitor (IC₅₀: 40 μM). L803-mts also reduces Aβ deposits and ameliorates cognitive deficits in 5XFAD mice. L803-mts shows antidepressive effect in the forced swimming test .

HY-P10605

GSK3β-peptide	Akt GSK-3	Cancer
GSK3β-peptide is a substrate mimetic peptide of glycogen synthase kinase 3-β (GSK3-β) that can bind to the active site of *GSK3-β* and mimic the behavior of a real substrate. GSK3β-peptide can be used to develop substrate mimetic inhibitors of Akt as potential anticancer drugs .

HY-P10971

Nef-M1	CXCR Apoptosis VEGFR GSK-3 Cadherin Caspase	Cancer
Nef-M1 (Nef-Motif-1) is an antagonist peptide targeting CXCR4 and an apoptosis inducer derived from a myristoylated protein encoded by the nef gene in HIV. Nef-M1 inhibits tumor angiogenesis and epithelial-mesenchymal transition (EMT). Nef-M1 activates the apoptosis pathway by increasing the level of caspase-3 in cancer cells. Nef-M1 simultaneously inhibits VEGF-A, *p-GSK-3β* and vimentin, and enhances E-cadherin, thereby inhibiting angiogenesis and EMT processes. Nef-M1 can be used in the study of colorectal cancer and breast cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-117025A

Manzamine A hydrochloride 1 Publications Verification Keramamine A hydrochloride	Structural Classification Neurological Disease Classification of Application Fields Source classification Marine natural products Pyridine Alkaloids Indole Alkaloids Infection Alkaloids Piperidine Alkaloids Animals Sponge Disease Research Fields	GSK-3 CDK Parasite Proton Pump HSV Autophagy
Manzamine A hydrochloride, an orally active beta-carboline alkaloid, inhibits specifically *GSK-3β* and CDK-5 with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. Manzamine A hydrochloride also shows potent activity against HSV-1 .

HY-117025

Manzamine A 1 Publications Verification Keramamine A	Infection Alkaloids Structural Classification Neurological Disease Classification of Application Fields Animals Marine natural products Sponge Disease Research Fields Cancer	GSK-3 CDK Parasite Proton Pump HSV Autophagy
Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically *GSK-3β* and CDK-5 with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1 .

HY-N6973

Boldine 1 Publications Verification	Alkaloids Structural Classification Classification of Application Fields Source classification Phenols Polyphenols Plants Lauraceae Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Litsea cubeba (Lour.) Pers.	RANKL/RANK Apoptosis
Boldine is an apomorphine isoquinoline alkaloid extracted from the root of the pheasant pepper (Litsea cubeba). Boldine is an oral effective antioxidant, anti-inflammatory, antitumor agent, and can inhibit osteoclast formation. Boldine induces apoptosis of human bladder cancer cells by regulating ERK, AKT and *GSK-3β. Boldine ameliorates bone destruction by down-regulating the OPG/RANKL/RANK* signaling pathway. It can be used in rheumatoid arthritis research .

HY-N0721

Neoandrographolide Neoandrographiside	Structural Classification Andrographis paniculata (Burm. F.) Nees Acanthaceae Classification of Application Fields Terpenoids Source classification Diterpenoids Plants Inflammation/Immunology Disease Research Fields	ERK p38 MAPK JNK NF-κB PI3K PPAR GSK-3 CaMK NO Synthase Reactive Oxygen Species (ROS) Apoptosis
Neoandrographolide is a diterpenoid compound isolated from Andrographis paniculata. Neoandrographolide inhibits osteoclasts differentiation and bone resorption through inhibition of *MAPK/NF-κB/PI3K/AKT/GSK3β/PPAR/CAMK* signaling pathway. Neoandrographolide inhibits apoptosis in rat embryonic ventricular cardiomyocytes. Neoandrographolide inhibits iNOS and the generation of ROS, activates eNOS, exhibiting anti-inflammatory and hypolipidemic activity .

HY-N6064

Polygalacin D 1 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Source classification Platycodon grandiflorus (Jacq.) A. DC. Campanulaceae Plants Disease Research Fields Cancer	Apoptosis IAP
Polygalacin D (PGD) is a bioactive compound isolated from Platycodon grandiflorum with anticancer and anti-proliferative properties. PGD suppresses the expression of the IAP family of proteins including survivin, cIAP-1 and cIAP-2 and blocks the PI3K/Akt pathway by inhibiting the phosphorylation of GSK3β, Akt and the expression of PI3K. Polygalacin D induces apoptosis

HY-W013812

Ethyl linoleate Linoleic Acid ethyl ester; Mandenol	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Gramineae Source classification Setaria italica Plants Disease Research Fields	Tyrosinase Akt GSK-3 β-catenin Biochemical Assay Reagents NF-κB Heme Oxygenase (HO)
Ethyl linoleate (Linoleic Acid ethyl ester) is an orally active unsaturated fatty acid. Ethyl linoleate inhibits the *Akt/GSK3β/β-catenin* signaling pathway and the activation of NF-κB. Ethyl linoleate induces heme oxygenase-1 and inhibits tyrosinase. Ethyl linoleate has whitening and anti-inflammatory effects. Ethyl linoleate promotes compound absorption. Ethyl linoleate has a significant influence on atherosclerosis. Ethyl linoleate is used in the research of inflammatory diseases. Ethyl linoleate can be used in cosmetics

HY-N0677

Dehydroandrographolide succinate	Structural Classification Andrographis paniculata (Burm. F.) Nees Acanthaceae Classification of Application Fields Terpenoids Source classification Diterpenoids Plants Inflammation/Immunology Disease Research Fields Cancer	Influenza Virus Prostaglandin Receptor Akt GSK-3
Dehydroandrographolide succinate can be extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used in research for viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect. Dehydroandrographolide succinate exerts antithrombotic effect. Dehydroandrographolide succinate significantly inhibits the platelet aggregation rate (ED₅₀ = 386.9 mg/kg) by decreasing TXB₂ levels. Dehydroandrographolide succinate mitigates muscle astrophy via the *Akt/GSK3β* and MuRF-1 pathways .

HY-N6866

Gomisin N	Structural Classification Neurological Disease Classification of Application Fields Source classification Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Inflammation/Immunology Disease Research Fields Cancer	Apoptosis AMPK Akt PERK Keap1-Nrf2 Caspase PARP GSK-3 NO Synthase Interleukin Related
Gomisin N is an orally active lignan compound. Gomisin N can be isolated from Schisandra chinensis. Gomisin N induces Apoptosis in a variety of cells. Gomisin N activates AMPK, Akt, MAPK/ERK, Nrf2, caspase-3 and PARP-1. Gomisin N inhibits *GSK3β, nitric oxide (NO), and proinflammatory cytokines (IL-1β, IL-6, TNF-α*). Gomisin N has anti-inflammatory, antioxidant, anti-obesity, anti-diabetic, and anti-melanogenesis activities. Gomisin N has anti-tumor activity against cervical cancer and liver cancer. Gomisin N improves Alzheimer's disease .

HY-133102

Dihydronarwedine Lycoraminone	Structural Classification Alkaloids Other Alkaloids Source classification Narcissus pseudonarcissus L. Plants Amaryllidaceae	GSK-3
Dihydronarwedine (Lycoraminone) is the alkaloid. Dihydronarwedine inhibits 39% activity of glycogen synthase kinase-3β (GSK-3β) at a concentration of 10 μM .

HY-N0721R

Neoandrographolide (Standard) Neoandrographiside (Standard)	Structural Classification Andrographis paniculata (Burm. F.) Nees Acanthaceae Terpenoids Source classification Diterpenoids Plants	Reference Standards ERK p38 MAPK JNK NF-κB PI3K PPAR GSK-3 NO Synthase Reactive Oxygen Species (ROS) Apoptosis
Neoandrographolide (Standard) is the analytical standard of Neoandrographolide. This product is intended for research and analytical applications. Neoandrographolide is a diterpenoid compound isolated from Andrographis paniculata. Neoandrographolide inhibits osteoclasts differentiation and bone resorption through inhibition of *MAPK/NF-κB/PI3K/AKT/GSK3β/PPAR/CAMK* signaling pathway. Neoandrographolide inhibits apoptosis in rat embryonic ventricular cardiomyocytes. Neoandrographolide inhibits iNOS and the generation of ROS, activates eNOS, exhibiting anti-inflammatory and hypolipidemic activity .

HY-N7676

Marein 2 Publications Verification	Cardiovascular Disease Structural Classification Chalcones Flavonoids other families Neurological Disease Classification of Application Fields Source classification Phenols Polyphenols Plants Disease Research Fields	AMPK HDAC
Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC₅₀ of 100 μM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects .

HY-N0753

Eupalinolide B	Structural Classification Classification of Application Fields Melilotus albus Desr. Terpenoids Sesquiterpenes Source classification Plants Compositae Disease Research Fields Cancer	Others Apoptosis Autophagy Reactive Oxygen Species (ROS) GSK-3 β-catenin MAP3K JNK NF-κB p38 MAPK
Eupalinolide B is a germ sesquiterpene. Eupalinolide B can be isolated from Eupatorium lindleyanum. Eupalinolide B induces Apoptosis, elevates ROS, promotes Autophagy. regulates *GSK-3β/β-catenin, targets UBE2D3* and TAK1, activates ROS-ER-JNK, inhibits NF-κB and MAPKs. Eupalinolide B has anticancer activity against pancreatic cancer and liver cancer. Eupalinolide B relieves rheumatoid arthritis, acute lung injury, periodontitis, depression .

Cat. No.	Product Name	Chemical Structure

HY-10512S

AR-A014418-d3
AR-A014418-d₃ is the deuterium labeled AR-A014418. AR-A014418 is a potent, selective, and ATP-competitive GSK3β inhibitor (IC₅₀=104 nM; K_i=38 nM) .

HY-B1619S

Cromolyn-d5

Cromolyn-d₅ (Cromoglycate-d₅) is the deuterium labeled Cromolyn (HY-B1619). Cromolyn (Cromoglycate) is an orally active GSK-3β inhibitor with an IC₅₀ of 2.0 μM. Cromolyn is also a mast cell stabilizer that can inhibit the release of mediators from mast cells, regulate reflex bronchoconstriction, and reduce non-specific bronchial hyperreactivity, and Cromolyn can be used in the research of bronchial asthma. In addition, Cromolyn has multiple activities such as anti-inflammatory, anti-allergic, anti-histamine, anti-cancer, and neuroprotective effects .

HY-B0712S1

Ceftriaxone-13C2,d3 triethylammonium salt

Ceftriaxone- ¹³C₂,d₃ triethylammonium salt is ¹³C and deuterated labeled Ceftriaxone (HY-B0712). Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC₅₀ value of 0.78 mM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks